SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
Condition: Metastatic Renal Cell Carcinoma Interventions: Drug: Ipilimumab; Radiation: SBRT Sponsors: Ontario Clinical Oncology Group (OCOG); Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Research | Urology & Nephrology | Yervoy